Abstract: OBJECTIVE To investigate the combined effect and significance of pegylated interferon combined with ribavirin in the treatment of patients with chronic hepatitis C virus infection, so as to provide references for clinical treatment. METHODS A total of 98 patients with chronic hepatitis C virus infection in our hospital from Jan. 2013 to Dec. 2015 were selected. According to different clinical drug treatment regimens, the patients were randomly divided into observation group (n=48) and control group (n=50). The patients in control group were treated with recombinant human interferon combined with ribavirin, and the patients in observation group were treated with pegylated interferon combined with ribavirin. The levels of immune factors and adverse events of the patients in the two groups were compared and analyzed. RESULTS The levels of T cell subsets of CD₃⁺, CD₄⁺, and CD₄⁺/CD₈⁺ of observation group were significantly increased after the treatment, and the level of CD₈⁺ was decreased, with significant differences (P<0.05). The incidence of adverse reactions in observation group was similar as control group, the difference was not significant. CONCLUSION Pegylated interferon combined with ribavirin has very important clinical treatment values in improving clinical outcomes and regulating the levels of immune factors for patients with chronic hepatitis C virus infection.